Cordyceps militaris Treatment Preserves Renal Function in Type 2 Diabetic Nephropathy Mice

PLoS One. 2016 Nov 10;11(11):e0166342. doi: 10.1371/journal.pone.0166342. eCollection 2016.


Diabetic nephropathy is derived from long-term effects of high blood glucose on kidney function in type 2 diabetic patients. Several antidiabetic drugs and herbal medications have failed to prevent episodes of DN. Hence, this study aimed to further investigate the renal injury-reducing effect of antidiabetic CmNo1, a novel combination of powders of fruiting bodies and mycelia of Cordyceps militaris. After being administered with streptozotocin-nicotinamide and high-fat-diet, the diabetic nephropathy mouse model displayed elevated blood glucose and renal dysfunction markers including serum creatinine and kidney-to-body weight ratio. These elevated markers were significantly mitigated following 8 weeks CmNo1 treatment. Moreover, the chronic hyperglycemia-induced pathological alteration in renal tissue were also ameliorated. Besides, immunohistochemical study demonstrated a substantial reduction in elevated levels of carboxymethyl lysine, an advanced glycation end product. Elevated collagenous deposition in DN group was also attenuated through CmNo1 administration. Moreover, the enhanced levels of transforming growth factor-β1, a fibrosis-inducing protein in glomerulus were also markedly dampened. Furthermore, auxiliary risk factors in DN like serum triglycerides and cholesterol were found to be increased but were decreased by CmNo1 treatment. Conclusively, the results suggests that CmNo1 exhibit potent and efficacious renoprotective action against hyperglycemia-induced DN.

MeSH terms

  • Animals
  • Biological Products / chemistry
  • Biological Products / therapeutic use*
  • Collagen / analysis
  • Cordyceps / chemistry*
  • Diabetes Mellitus, Experimental / blood
  • Diabetes Mellitus, Experimental / complications
  • Diabetes Mellitus, Experimental / drug therapy*
  • Diabetes Mellitus, Experimental / physiopathology
  • Diabetes Mellitus, Type 2 / blood
  • Diabetes Mellitus, Type 2 / complications
  • Diabetes Mellitus, Type 2 / drug therapy*
  • Diabetes Mellitus, Type 2 / physiopathology
  • Diabetic Nephropathies / blood
  • Diabetic Nephropathies / complications
  • Diabetic Nephropathies / drug therapy*
  • Diabetic Nephropathies / physiopathology
  • Fruiting Bodies, Fungal / chemistry
  • Glycation End Products, Advanced / analysis
  • Glycogen / analysis
  • Hypoglycemic Agents / chemistry
  • Hypoglycemic Agents / therapeutic use*
  • Kidney / drug effects*
  • Kidney / physiopathology
  • Kidney Function Tests
  • Mice
  • Mice, Inbred C57BL
  • Mycelium / chemistry
  • Streptozocin
  • Transforming Growth Factor beta1 / analysis


  • Biological Products
  • Glycation End Products, Advanced
  • Hypoglycemic Agents
  • Transforming Growth Factor beta1
  • Streptozocin
  • Glycogen
  • Collagen

Grant support

Supported by the following agencies (grant no.): National Science Council, Taiwan (NSC 99-2628-B-038-010-MY3, 101-2314-B-038-023, 102-2314-B-038-058 and 102-2314-B-038-015) and Department of Health, Taiwan. (DOH102-TD-PB-111-NSC009). URL NSC: URL DoH Taiwan: